DEBATE: Sequencing Small Molecules Is the Way ... - CLL Support
DEBATE: Sequencing Small Molecules Is the Way to Go, by Dr. Jennifer R.Brown at the Society of Hematologic Oncology 2022 Annual Meeting
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
From the New England Journal of Medicine 10th December 2023
"The CLL treatment landscape has...
Related Posts
Unmutated patients on venetoclax?- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista- Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL
- Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
